We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
NME1 is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: 0.98
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
0.32
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
9%
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
10%
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
291.6
Number of samples
141
Samples
Sample
Description
TPM
TCGA-06-0178-01A
38 years, male, white, stage:'--, dead, 2681 days
1172.1
TCGA-27-2524-01A
56 years, male, white, stage:'--, dead, 231 days
637.1
TCGA-27-1831-01A
66 years, male, white, stage:'--, dead, 505 days
615.2
TCGA-06-0219-01A
67 years, male, white, stage:'--, dead, 22 days
587.1
TCGA-12-0616-01A
36 years, female, white, stage:'--, dead, 448 days
562.6
TCGA-12-3652-01A
60 years, male, white, stage:'--, dead, 1062 days
544.2
TCGA-12-3650-01A
46 years, male, white, stage:'--, dead, 333 days
502.1
TCGA-06-5413-01A
67 years, male, white, stage:'--, alive, 268 days
498.1
TCGA-28-5204-01A
72 years, male, white, stage:'--, dead, 454 days
491.7
TCGA-02-2483-01A
43 years, male, asian, stage:'--, alive, 466 days
491.3
TCGA-06-0238-01A
46 years, male, white, stage:'--, dead, 405 days
467.9
TCGA-14-1825-01A
70 years, male, white, stage:'--, dead, 232 days
465.1
TCGA-27-2523-01A
63 years, male, white, stage:'--, dead, 489 days
454.0
TCGA-28-5208-01A
52 years, male, white, stage:'--, dead, 544 days
446.8
TCGA-06-0744-01A
66 years, male, white, stage:'--, dead, 1426 days
433.0
TCGA-27-1835-01A
53 years, female, white, stage:'--, dead, 648 days
430.7
TCGA-06-0156-01A
57 years, male, white, stage:'--, dead, 178 days
426.8
TCGA-06-5416-01A
23 years, female, white, stage:'--, alive, 204 days
424.1
TCGA-06-0686-01A
53 years, male, white, stage:'--, dead, 432 days
418.3
TCGA-27-2526-01A
79 years, female, white, stage:'--, dead, 87 days
415.0
TCGA-06-5856-01A
58 years, male, white, stage:'--, dead, 114 days
413.0
TCGA-14-1829-01A
57 years, male, black or african american, stage:'--, alive, 218 days
406.4
TCGA-32-5222-01A
66 years, male, white, stage:'--, dead, 585 days
401.1
TCGA-41-2572-01A
67 years, male, white, stage:'--, dead, 406 days
392.8
TCGA-06-2558-01A
75 years, female, white, stage:'--, dead, 380 days
390.5
TCGA-06-0174-01A
54 years, male, white, stage:'--, dead, 98 days
386.9
TCGA-27-2521-01A
34 years, male, white, stage:'--, dead, 510 days
381.3
TCGA-76-4931-01A
70 years, female, white, stage:'--, dead, 279 days
379.9
TCGA-06-5411-01A
51 years, male, white, stage:'--, dead, 254 days
379.1
TCGA-14-0817-01A
69 years, female, white, stage:'--, dead, 164 days
378.5
TCGA-15-0742-01A
65 years, male, white, stage:'--, dead, 419 days
372.2
TCGA-06-2563-01A
72 years, female, white, stage:'--, alive, 932 days
372.1
TCGA-76-4932-01A
50 years, female, white, stage:'--, dead, 1458 days
365.4
TCGA-12-5295-01A
60 years, female, white, stage:'--, dead, 454 days
364.6
TCGA-28-5209-01A
66 years, female, white, stage:'--, alive, 442 days
362.2
TCGA-06-5408-01A
54 years, female, white, stage:'--, dead, 357 days
351.7
TCGA-28-5220-01A
67 years, male, white, stage:'--, dead, 388 days
348.7
TCGA-19-2624-01A
51 years, male, white, stage:'--, dead, 5 days
340.8
TCGA-06-0745-01A
59 years, male, white, stage:'--, dead, 239 days
339.8
TCGA-12-5299-01A
56 years, female, white, stage:'--, dead, 98 days
335.6
TCGA-19-4065-01A
36 years, male, white, stage:'--, alive, 214 days
329.2
TCGA-06-2559-01A
83 years, male, white, stage:'--, dead, 150 days
328.2
TCGA-14-0787-01A
69 years, male, asian, stage:'--, dead, 68 days
326.0
TCGA-19-2629-01A
60 years, male, white, stage:'--, dead, 737 days
323.4
TCGA-06-5418-01A
75 years, female, white, stage:'--, dead, 83 days
322.3
TCGA-12-0618-01A
49 years, male, white, stage:'--, dead, 395 days
321.5
TCGA-02-2485-01A
53 years, male, black or african american, stage:'--, alive, 470 days
321.3
TCGA-26-5133-01A
59 years, male, white, stage:'--, alive, 452 days
320.8
TCGA-06-0644-01A
71 years, male, black or african american, stage:'--, dead, 384 days
319.2
TCGA-28-5215-01A
62 years, female, white, stage:'--, dead, 335 days
319.1
TCGA-06-0138-01A
43 years, male, white, stage:'--, dead, 737 days
313.6
TCGA-32-2634-01A
82 years, male, white, stage:'--, alive, 693 days
306.0
TCGA-41-5651-01A
59 years, female, black or african american, stage:'--, dead, 460 days
305.0
TCGA-06-0211-01A
47 years, male, white, stage:'--, dead, 360 days
302.9
TCGA-06-2562-01A
81 years, male, white, stage:'--, dead, 382 days
301.2
TCGA-41-2571-01A
89 years, male, white, stage:'--, dead, 26 days
298.3
TCGA-28-5216-01A
52 years, male, white, stage:'--, alive, 415 days
297.1
TCGA-27-1837-01A
36 years, male, white, stage:'--, dead, 427 days
295.4
TCGA-76-4925-01A
76 years, male, white, stage:'--, dead, 146 days
288.6
TCGA-76-4927-01A
58 years, male, white, stage:'--, dead, 535 days
283.7
TCGA-26-5135-01A
72 years, female, white, stage:'--, dead, 270 days
281.0
TCGA-27-2528-01A
62 years, male, white, stage:'--, dead, 480 days
274.2
TCGA-76-4929-01A
76 years, female, white, stage:'--, dead, 111 days
271.8
TCGA-19-2619-01A
55 years, female, black or african american, stage:'--, alive, 294 days
270.5
TCGA-12-3653-01A
34 years, female, white, stage:'--, dead, 442 days
268.7
TCGA-32-1982-01A
76 years, female, white, stage:'--, dead, 142 days
265.5
TCGA-06-5414-01A
61 years, male, white, stage:'--, alive, 273 days
264.9
TCGA-06-2569-01A
24 years, female, black or african american, stage:'--, alive, 13 days
263.5
TCGA-06-0157-01A
63 years, female, white, stage:'--, dead, 97 days
262.1
TCGA-32-2632-01A
80 years, male, white, stage:'--, dead, 269 days
262.0
TCGA-12-0821-01A
62 years, male, white, stage:'--, dead, 323 days
261.5
TCGA-06-5417-01A
45 years, female, white, stage:'--, alive, 155 days
260.9
TCGA-32-2616-01A
48 years, female, white, stage:'--, dead, 224 days
260.4
TCGA-19-1390-01A
63 years, female, white, stage:'--, dead, 772 days
260.3
TCGA-06-2565-01A
59 years, male, asian, stage:'--, dead, 506 days
260.1
TCGA-27-1832-01A
59 years, female, white, stage:'--, dead, 300 days
252.5
TCGA-06-2570-01A
21 years, female, white, stage:'--, alive, 958 days
250.5
TCGA-06-5412-01A
78 years, female, white, stage:'--, dead, 138 days
249.0
TCGA-06-0125-01A
63 years, female, white, stage:'--, dead, 1448 days
245.6
TCGA-28-1753-01A
53 years, male, white, stage:'--, alive, 37 days
245.0
TCGA-14-0871-01A
74 years, female, white, stage:'--, dead, 880 days
243.8
TCGA-06-0141-01A
62 years, male, white, stage:'--, dead, 313 days
243.0
TCGA-27-2519-01A
48 years, male, white, stage:'--, dead, 550 days
239.9
TCGA-06-0645-01A
55 years, female, white, stage:'--, dead, 175 days
239.0
TCGA-28-5207-01A
71 years, male, white, stage:'--, dead, 343 days
238.0
TCGA-06-0646-01A
60 years, male, white, stage:'--, dead, 175 days
237.6
TCGA-06-5859-01A
63 years, male, white, stage:'--, alive, 139 days
234.4
TCGA-02-2486-01A
64 years, male, white, stage:'--, dead, 618 days
232.7
TCGA-26-5139-01A
65 years, female, white, stage:'--, alive, 48 days
232.1
TCGA-14-2554-01A
52 years, female, white, stage:'--, dead, 532 days
231.5
TCGA-06-0750-01A
43 years, male, white, stage:'--, dead, 28 days
230.4
TCGA-41-3915-01A
48 years, male, white, stage:'--, dead, 360 days
227.7
TCGA-14-1823-01A
58 years, female, white, stage:'--, dead, 543 days
226.9
TCGA-06-0129-01A
30 years, male, asian, stage:'--, dead, 1024 days
222.4
TCGA-06-0743-01A
69 years, male, white, stage:'--, dead, 803 days
222.1
TCGA-06-2557-01A
76 years, male, black or african american, stage:'--, dead, 33 days
221.5
TCGA-06-0168-01A
59 years, female, white, stage:'--, dead, 598 days
216.0
TCGA-06-2564-01A
50 years, male, white, stage:'--, alive, 181 days
215.7
TCGA-32-4213-01A
47 years, female, white, stage:'--, alive, 604 days
215.4
TCGA-32-2638-01A
67 years, male, white, stage:'--, dead, 766 days
211.6
TCGA-06-0878-01A
74 years, male, white, stage:'--, alive, 218 days
211.3
TCGA-28-5218-01A
63 years, male, white, stage:'--, dead, 157 days
211.2
TCGA-06-0187-01A
69 years, male, white, stage:'--, dead, 828 days
210.7
TCGA-06-2561-01A
53 years, female, white, stage:'--, dead, 537 days
207.6
TCGA-28-2509-01A
77 years, female, white, stage:'--, alive, 145 days
206.5
TCGA-15-1444-01A
21 years, male, white, stage:'--, dead, 1537 days
206.0
TCGA-06-0139-01A
40 years, male, white, stage:'--, dead, 362 days
205.5
TCGA-28-2514-01A
45 years, male, asian, stage:'--, alive, 160 days
205.1
TCGA-06-0130-01A
54 years, male, white, stage:'--, dead, 394 days
201.1
TCGA-06-5410-01A
72 years, female, white, stage:'--, dead, 108 days
197.6
TCGA-06-0882-01A
30 years, male, white, stage:'--, dead, 632 days
196.6
TCGA-16-0846-01A
85 years, male, white, stage:'--, dead, 119 days
195.9
TCGA-06-0210-01A
72 years, female, white, stage:'--, dead, 225 days
194.6
TCGA-28-2513-01A
69 years, female, white, stage:'--, alive, 222 days
193.1
TCGA-12-0619-01A
60 years, male, white, stage:'--, dead, 1062 days
186.0
TCGA-41-4097-01A
63 years, female, white, stage:'--, dead, 6 days
185.2
TCGA-32-2615-01A
62 years, male, white, stage:'--, dead, 485 days
182.9
TCGA-02-0047-01A
78 years, male, white, stage:'--, dead, 448 days
180.7
TCGA-02-0055-01A
62 years, female, white, stage:'--, dead, 76 days
180.1
TCGA-06-5858-01A
45 years, female, white, stage:'--, alive, 187 days
178.6
TCGA-14-1034-01A
60 years, female, stage:'--, dead, 485 days
177.9
TCGA-06-2567-01A
65 years, male, white, stage:'--, dead, 133 days
177.9
TCGA-06-0184-01A
63 years, male, white, stage:'--, dead, 2126 days
177.6
TCGA-32-1970-01A
59 years, male, white, stage:'--, dead, 468 days
177.0
TCGA-06-0747-01A
53 years, male, white, stage:'--, dead, 82 days
176.8
TCGA-06-0190-01A
62 years, male, white, stage:'--, dead, 317 days
176.6
TCGA-26-5132-01A
74 years, male, white, stage:'--, alive, 286 days
175.5
TCGA-19-2625-01A
76 years, female, white, stage:'--, dead, 124 days
172.8
TCGA-27-1834-01A
56 years, male, white, stage:'--, dead, 1233 days
166.8
TCGA-19-5960-01A
56 years, male, white, stage:'--, dead, 455 days
162.6
TCGA-27-1830-01A
57 years, male, white, stage:'--, dead, 154 days
161.4
TCGA-06-0749-01A
50 years, male, black or african american, stage:'--, dead, 82 days
160.6
TCGA-32-1980-01A
72 years, male, white, stage:'--, dead, 36 days
158.3
TCGA-06-0158-01A
73 years, male, white, stage:'--, dead, 329 days
145.4
TCGA-08-0386-01A
74 years, male, white, stage:'--, dead, 548 days
144.1
TCGA-06-0132-01A
49 years, male, white, stage:'--, dead, 771 days
139.6
TCGA-14-0789-01A
54 years, male, white, stage:'--, dead, 342 days
133.4
TCGA-26-5134-01A
74 years, male, white, stage:'--, alive, 167 days
133.3
TCGA-19-2620-01A
70 years, male, white, stage:'--, dead, 148 days
118.2
TCGA-26-1442-01A
43 years, male, white, stage:'--, alive, 953 days
89.2
TCGA-06-1804-01A
81 years, female, white, stage:'--, dead, 414 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
NME1 is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: 0.99
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
0.30
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
29%
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
24%
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
13.3
Number of samples
58
Samples
Sample
Description
TPM
AK156
N, NA, stage:NA, dead, 330 days
30.4
AK142
N, NA, stage:NA, alive, 90 days
25.6
AK002
N, NA, stage:NA, dead, 570 days
24.4
AK199
N, NA, stage:NA, alive, 1860 days
20.9
AK149
N, NA, stage:NA, dead, 420 days
19.7
AK079
N, NA, stage:NA, dead, 210 days
19.1
AK213
N, NA, stage:NA, alive, 2010 days
19.0
AK173
N, NA, stage:NA, dead, 180 days
18.7
AK123
N, NA, stage:NA, dead, 180 days
18.5
AK051
N, NA, stage:NA, dead, 360 days
17.9
AK185
N, NA, stage:NA, alive, 330 days
17.7
AK165
N, NA, stage:NA, alive, 360 days
17.3
AK072
N, NA, stage:NA, dead, 150 days
17.3
AK043
N, NA, stage:NA, alive, 660 days
17.3
AK068
N, NA, stage:NA, alive, 360 days
17.0
AK183
N, NA, stage:NA, alive, 360 days
16.5
AK074
N, NA, stage:NA, alive, 300 days
16.3
AK003
N, NA, stage:NA, dead, 600 days
15.4
AK049
N, NA, stage:NA, dead, 180 days
15.1
AK098
N, NA, stage:NA, dead, 660 days
14.7
AK071
N, NA, stage:NA, dead, 540 days
14.5
AK139
N, NA, stage:NA, dead, 270 days
14.5
AK099
N, NA, stage:NA, dead, 420 days
13.5
AK035
N, NA, stage:NA, dead, 210 days
13.3
AK133
N, NA, stage:NA, dead, 360 days
13.2
AK188
N, NA, stage:NA, alive, 420 days
13.2
AK231
N, NA, stage:NA, dead, 240 days
13.1
AK124
N, NA, stage:NA, alive, 1920 days
12.9
AK134
N, NA, stage:NA, dead, 360 days
12.9
AK100
N, NA, stage:NA, alive, 960 days
12.9
AK218
N, NA, stage:NA, dead, 180 days
12.7
AK076
N, NA, stage:NA, alive, 660 days
12.1
AK226
N, NA, stage:NA, dead, 360 days
12.0
AK081
N, NA, stage:NA, dead, 180 days
12.0
AK227
N, NA, stage:NA, alive, 300 days
11.9
AK055
N, NA, stage:NA, dead, 240 days
11.6
AK053
N, NA, stage:NA, dead, 300 days
11.5
AK089
N, NA, stage:NA, dead, 330 days
11.2
AK195
N, NA, stage:NA, dead, 390 days
11.1
AK066
N, NA, stage:NA, alive, 960 days
10.8
AK041
N, NA, stage:NA, alive, 810 days
10.7
AK178
N, NA, stage:NA, dead, 240 days
10.5
AK153
N, NA, stage:NA, dead, 240 days
10.1
AK216
N, NA, stage:NA, dead, 360 days
9.6
AK236
N, NA, stage:NA, dead, 360 days
9.4
AK030
N, NA, stage:NA, dead, 120 days
9.0
AK158
N, NA, stage:NA, dead, 360 days
8.9
AK088
N, NA, stage:NA, dead, 360 days
8.8
AK117
N, NA, stage:NA, dead, 210 days
7.9
AK205
N, NA, stage:NA, dead, 120 days
7.7
AK102
N, NA, stage:NA, alive, 1740 days
7.3
AK103
N, NA, stage:NA, alive, 1320 days
7.1
AK167
N, NA, stage:NA, dead, 180 days
7.0
AK085
N, NA, stage:NA, alive, 660 days
6.7
AK091
N, NA, stage:NA, dead, 210 days
6.7
AK005
N, NA, stage:NA, dead, 240 days
6.4
AK015
N, NA, stage:NA, alive, 720 days
5.7
AK006
N, NA, stage:NA, dead, 360 days
3.7
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0221180003
Tumor
0.7
CPT0219080004
Tumor
0.5
CPT0217710008
Tumor
0.5
CPT0206110003
Tumor
0.4
CPT0189750004
Tumor
0.4
CPT0186100003
Tumor
0.4
CPT0189650004
Tumor
0.3
CPT0217880003
Tumor
0.3
CPT0204420003
Normal
0.3
CPT0087730003
Tumor
0.3
CPT0161730003
Tumor
0.3
CPT0217000004
Tumor
0.3
CPT0087950003
Tumor
0.3
CPT0168080003
Tumor
0.3
CPT0093590003
Tumor
0.3
CPT0093510003
Tumor
0.3
CPT0204330003
Normal
0.3
CPT0218770003
Tumor
0.3
CPT0162020003
Tumor
0.3
CPT0071100003
Tumor
0.2
CPT0225760003
Tumor
0.2
CPT0125570003
Tumor
0.2
CPT0204380003
Normal
0.2
CPT0205450004
Tumor
0.2
CPT0204360003
Normal
0.2
CPT0205570003
Tumor
0.2
CPT0204390003
Normal
0.2
CPT0125510003
Tumor
0.2
CPT0089150003
Tumor
0.2
CPT0204370003
Normal
0.2
CPT0204400003
Normal
0.2
CPT0189460003
Tumor
0.2
CPT0087570003
Tumor
0.2
CPT0204410003
Normal
0.1
CPT0228220003
Tumor
0.1
CPT0217100003
Tumor
0.1
CPT0162100003
Tumor
0.1
CPT0204340003
Normal
0.1
CPT0206780003
Tumor
0.1
CPT0217060003
Tumor
0.1
CPT0182500003
Tumor
0.1
CPT0205780003
Tumor
0.1
CPT0168380003
Tumor
0.1
CPT0207030003
Tumor
0.1
CPT0087680003
Tumor
0.1
CPT0168830003
Tumor
0.1
CPT0225730003
Tumor
0.1
CPT0123530003
Tumor
0.1
CPT0078580003
Tumor
0.0
CPT0224330003
Tumor
0.0
CPT0125220003
Tumor
0.0
CPT0127480003
Tumor
0.0
CPT0208980003
Tumor
0.0
CPT0189570004
Tumor
0.0
CPT0224390004
Tumor
0.0
CPT0093450003
Tumor
0.0
CPT0206880003
Tumor
0.0
CPT0206560003
Tumor
0.0
CPT0093360003
Tumor
0.0
CPT0207090003
Tumor
0.0
CPT0199770003
Tumor
0.0
CPT0204350003
Normal
0.0
CPT0216920008
Tumor
0.0
CPT0175060003
Tumor
-0.1
CPT0217190003
Tumor
-0.1
CPT0168590003
Tumor
-0.1
CPT0064650003
Tumor
-0.1
CPT0217430008
Tumor
-0.1
CPT0205890003
Tumor
-0.1
CPT0206450003
Tumor
-0.1
CPT0224600003
Tumor
-0.1
CPT0079790003
Tumor
-0.1
CPT0167530003
Tumor
-0.1
CPT0189850004
Tumor
-0.1
CPT0064890003
Tumor
-0.1
CPT0182580003
Tumor
-0.1
CPT0002410011
Tumor
-0.1
CPT0209440003
Tumor
-0.1
CPT0205670004
Tumor
-0.1
CPT0104330003
Tumor
-0.2
CPT0206000004
Tumor
-0.2
CPT0104220003
Tumor
-0.2
CPT0218690004
Tumor
-0.2
CPT0218960004
Tumor
-0.2
CPT0167860004
Tumor
-0.2
CPT0168480003
Tumor
-0.2
CPT0190360004
Tumor
-0.2
CPT0167750004
Tumor
-0.2
CPT0196850003
Tumor
-0.2
CPT0218670003
Tumor
-0.2
CPT0182550003
Tumor
-0.2
CPT0162140003
Tumor
-0.2
CPT0092440003
Tumor
-0.2
CPT0218830004
Tumor
-0.3
CPT0167970003
Tumor
-0.3
CPT0167640003
Tumor
-0.3
CPT0206330003
Tumor
-0.3
CPT0127420003
Tumor
-0.3
CPT0206670004
Tumor
-0.3
CPT0218890004
Tumor
-0.3
CPT0206230003
Tumor
-0.3
CPT0171580008
Tumor
-0.3
CPT0168720003
Tumor
-0.3
CPT0218330004
Tumor
-0.4
CPT0168270003
Tumor
-0.4
CPT0093550003
Tumor
-0.4
CPT0189250003
Tumor
-0.4
CPT0224540004
Tumor
-0.4
CPT0190240004
Tumor
-0.4
CPT0201710003
Tumor
-0.5
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
Antibody stainingi
Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells.
Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample.